Bioengineered bacterial outer membrane vesicles: What is their potential in cancer therapy?

Nanomedicine

Volumn 9, Issue 7, 2014, Pages 933-935

  Gujrati, Vipul B ^a   Jon, Sangyong ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

affibody; cancer therapy; drug delivery; outer membrane vesicle; small interfering RNA

Indexed keywords

BACTERIAL OUTER MEMBRANE; BIOENGINEERING; CANCER CELL; CANCER THERAPY; CANCER TISSUE; DRUG DELIVERY SYSTEM; MEMBRANE VESICLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; BACTERIA; CHEMISTRY; HUMAN; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; BACTERIA; BIOENGINEERING; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 84903846331     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.56     Document Type: Review

References (19)

1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007). (Pubitemid 350223348)
2. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010).
3. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 3(1), 16-20 (2009).
4. Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov. 10(7), 521-535 (2011).
5. Macdiarmid JA, Mugridge NB, Weiss JC et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 11(5), 431-445 (2007). (Pubitemid 46670079)
6. Wu W, Hsiao SC, Carrico ZM, Francis MB. Genome-free viral capsids as multivalent carriers for taxol delivery. Angew Chem. Int. Ed. 48(50), 9493-9497 (2009).
7. Tong GJ, Hsiao SC, Carrico ZM, Francis MB. Viral Capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J. Am. Chem. Soc. 131(31), 11174-11178 (2009).
8. Alvarez-Erviti L, Seow YQ, Yin HF, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29(4), 341-U179 (2011).
9. El Andaloussi S, Maeger I, Breakefield XO, Wood MJA. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12(5), 348-358 (2013).
10. Gujrati V, Kim S, Kim SH et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano 8(2), 1525-1537 (2014).
11. Lee EY, Choi DS, Kim KP, Gho YS. Proteomics in Gramnegative bacterial outer membrane vesicles. Mass Spectrom. Rev. 27(6), 535-555 (2008).
12. Kuehn MJ, Kesty NC. Bacterial outer membrane vesicles and the host-pathogen interaction. Gene Dev. 19(22), 2645-2655 (2005). (Pubitemid 41627932)
13. Kim JY, Doody AM, Chen DJ et al. Engineered bacterial outer membrane vesicles with enhanced functionality. J. Mol. Biol. 380(1), 51-66 (2008).
14. Chen DJ, Osterrieder N, Metzger SM et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl Acad. Sci. USA 107(7), 3099-3104 (2010).
15. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat. Immunol. 3(4), 354-359 (2002). (Pubitemid 34308623)
16. Somerville JE, Cassiano L, Darveau RP. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect. Immun. 67(12), 6583-6590 (1999).
17. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
18. Orlova A, Magnusson M, Eriksson TLJ et al. Tumor Imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66(8), 4339-4348 (2006).
19. Judge AD, Robbins M, Tavakoli I et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119(3), 661-673 (2009).